I-Mab ADR (IMAB): Price and Financial Metrics


Today's Latest Price: $37.16 USD

3.10 (-7.70%)

Updated Nov 24 4:00pm

Add IMAB to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

IMAB Stock Summary

  • IMAB's went public 0.84 years ago, making it older than just 0.13% of listed US stocks we're tracking.
  • With a price/sales ratio of 128.62, I-Mab has a higher such ratio than 97.37% of stocks in our set.
  • Over the past twelve months, IMAB has reported earnings growth of 266.84%, putting it ahead of 94.74% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to I-Mab are WATT, HTBX, ACRS, RESN, and CUE.
  • Visit IMAB's SEC page to see the company's official filings. To visit the company's web site, go to www.i-mabbiopharma.com.

IMAB Stock Price Chart Interactive Chart >

Price chart for IMAB

IMAB Price/Volume Stats

Current price $37.16 52-week high $47.46
Prev. close $40.26 52-week low $9.30
Day low $37.13 Volume 148,300
Day high $39.95 Avg. volume 140,249
50-day MA $39.20 Dividend yield N/A
200-day MA $26.82 Market Cap 2.12B

I-Mab ADR (IMAB) Company Bio

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

IMAB Latest News Stream

Event/Time News Detail
Loading, please wait...

IMAB Latest Social Stream

Loading social stream, please wait...

View Full IMAB Social Stream

Latest IMAB News From Around the Web

Below are the latest news stories about I-Mab that investors may wish to consider to help them evaluate IMAB as an investment opportunity.

I-Mab gets China NMPA nod to initiate early-stage study with lemzoparlimab in lymphoma

China National Medical Products Administration' ((NMPA)) signs off I-Mab' ([[IMAB]] -0.7%) investigational new drug application for lemzoparlimab (TJC4) to initiate a phase 1 trial in patients with relapsed or refractory advanced lymphoma.Additionally, a phase 1/2a clinical trial in patients with relapsed or refractory acute myeloid leukemia in China is currently underway with data expected in...

Seeking Alpha | September 21, 2020

I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma

SHANGHAI and GAITHERSBURG, Md., Sept. 21, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of…

PR Newswire | September 21, 2020

I-Mab Announces Upcoming Participation at September Conferences

SHANGHAI and GAITHERSBURG, Md., Sept. 8, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences…

PR Newswire | September 8, 2020

Week In Review: I-Mab Partners CD47 With AbbVie In $2 Billion Deal

Deals and Financings Shanghai's I-Mab (IMAB) out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie (ABBV) in a blockbuster $2 billion agreement. Separately, AbbVie also acquired right-of-first-refusal to two other CD47 molecules, which, if exercised, would each trigger a $500 million payment. And I-Mab raised $418 million in a...

ChinaBio Today on Seeking Alpha | September 6, 2020

Biopharma News: IMAB Stock Soars 4% on AbbVie Pact

I-Mab (IMAB) is seeing gains to IMAB stock on Friday after the biopharma company announced news of a deal with AbbVie (ABBV).

InvestorPlace | September 4, 2020

Read More 'IMAB' Stories Here

IMAB Price Returns

1-mo -9.78%
3-mo 18.95%
6-mo 49.06%
1-year N/A
3-year N/A
5-year N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7864 seconds.